Basel, Switzerland

Peter Gedeck

USPTO Granted Patents = 4 


Average Co-Inventor Count = 12.0

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2011-2017

Loading Chart...
Loading Chart...
4 patents (USPTO):

Title: Inventor Profile: Peter Gedeck

Introduction

Peter Gedeck is an innovative inventor based in Basel, Switzerland, known for his significant contributions to the pharmaceutical field. With four patents to his name, Gedeck has focused his research on treating diseases associated with the blockade of the epithelial sodium channel.

Latest Patents

Among his noteworthy inventions are his latest patents, which revolve around the use of pyrazine-2-carboxamide derivatives. These compounds, described as a compound of Formula I in free or salt or solvate form, are instrumental in treating diseases that respond positively to the blockade of the epithelial sodium channel. Furthermore, his patents encompass pharmaceutical compositions that include these compounds and processes for their preparation.

Career Highlights

Peter Gedeck is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis not only showcases his dedication to pharmaceutical innovation but also highlights his role in advancing medical treatments for various health conditions.

Collaborations

Throughout his career, Gedeck has collaborated with esteemed colleagues such as Gurdip Bhalay and Emma Budd. Together, they have contributed to pioneering research and development in their respective fields, demonstrating the importance of teamwork and collaboration in scientific advancements.

Conclusion

Peter Gedeck's inventive spirit and commitment to addressing critical health challenges have led to valuable patents that could significantly impact patient care. His ongoing work promises to further enhance our understanding of how to effectively manage diseases, solidifying his status as a notable figure in the realm of medical innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…